PATENT CLAIM ANALYSIS

Application Number: 16124069
Application Type: Utility
Filing Date: 2018-09
Publication Date: 2019-01
Patent Classification: ["514", "108000"]

Abstract:
Oral dosage forms of osteoclast inhibitors, such as zoledronic acid, in an acid or a salt form can be used to treat or alleviate pain or related conditions.

Claim (Index 16):
A method of delivering zoledronic acid to the blood, comprising: orally administering a dosage form comprising zoledronic acid, in a salt form to a human being in need of treatment with zoledronic acid, wherein the human being has fasted for at least one hour before the dosage form is orally administered and wherein the human being fasts for at least one hour after the dosage form is orally administered;\n with the proviso that the bioavailability of zoledronic acid as a property of the salt form, as measured in a reference dosage form, is no more than 4%, wherein the reference dosage form contains the zoledronic acid in the salt form and does not contain a bioavailability enhancer; with the proviso that the dosage form contains no less than 40 mg of the zoledronic acid in the salt form; and with the proviso that the bioavailability of zoledronic acid as a property of the salt form, as measured in the reference dosage form, is at least 1.1%.

Metadata:
- Claim Count in Document: 38.0
- Percentile: 97.0
- Lexical Diversity: 1.14815
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15403073', '15439774', '15416995', '15697267', '15897947']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8438509076441427
- 35 USC 102 Novelty (BERT): 0.6156564173706816
- Combined Prediction Score: 0.8210314586167966
- Mean Citation Score: 640.224188
- Max Citation Score: 644.8831
- Similarity Product: 489.3674508822918

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test